Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Next Previous
Trial Profile

A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Sep 2015 Status changed from planning to completed, as reported by European Clinical Trials Database (EudraCT2010-019033-98)
  • 06 Jul 2015 New trial record
  • 02 Jun 2015 Based on results of a phase I trial (see trial profile 700222282), investigators at the University of Utah are planning to conduct this phase II trial of intratumoural ipilimumab and aldesleukin in conjunction with systemic immunotherapy, according to an abstract presented at ASCO 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top